Todd Fox

878 total citations
20 papers, 672 citations indexed

About

Todd Fox is a scholar working on Immunology, Rheumatology and Economics and Econometrics. According to data from OpenAlex, Todd Fox has authored 20 papers receiving a total of 672 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 10 papers in Rheumatology and 4 papers in Economics and Econometrics. Recurrent topics in Todd Fox's work include Psoriasis: Treatment and Pathogenesis (13 papers), Spondyloarthritis Studies and Treatments (10 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Todd Fox is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (13 papers), Spondyloarthritis Studies and Treatments (10 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Todd Fox collaborates with scholars based in Switzerland, United States and Germany. Todd Fox's co-authors include Kristian Reich, C. Papavassilis, Tsen‐Fang Tsai, C.E.M. Griffiths, Andrew Blauvelt, Craig L. Leonardi, Jiaqing Huang, P.C.M. van de Kerkhof, Luminita Pricop and Iain B. McInnes and has published in prestigious journals such as Annals of the Rheumatic Diseases, PLoS Pathogens and Journal of the American Academy of Dermatology.

In The Last Decade

Todd Fox

20 papers receiving 661 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Todd Fox Switzerland	12	506	229	190	147	109	20	672
Hilde Carlier United States	12	390 0.8×	83 0.4×	380 2.0×	157 1.1×	84 0.8×	26	644
Francesco Loconsole Italy	14	445 0.9×	325 1.4×	110 0.6×	58 0.4×	73 0.7×	45	656
É. Bégon France	14	292 0.6×	297 1.3×	157 0.8×	51 0.3×	170 1.6×	49	714
Mark D. Herron United States	9	336 0.7×	269 1.2×	88 0.5×	26 0.2×	132 1.2×	14	622
Beatriz Pérez-Zafrilla Spain	13	233 0.5×	55 0.2×	243 1.3×	105 0.7×	119 1.1×	17	538
Géraldine Bart France	8	245 0.5×	135 0.6×	112 0.6×	47 0.3×	54 0.5×	26	493
Federica Ricceri Italy	13	261 0.5×	293 1.3×	98 0.5×	40 0.3×	136 1.2×	48	585
J.L. Sánchez‐Carazo Spain	14	268 0.5×	204 0.9×	73 0.4×	28 0.2×	108 1.0×	38	470
Consuelo Ortega Spain	8	301 0.6×	79 0.3×	50 0.3×	29 0.2×	68 0.6×	12	431
Saba Arshi Iran	13	247 0.5×	64 0.3×	56 0.3×	44 0.3×	55 0.5×	63	630

Countries citing papers authored by Todd Fox

Since Specialization

Citations

This map shows the geographic impact of Todd Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Fox more than expected).

Fields of papers citing papers by Todd Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Fox. The network helps show where Todd Fox may publish in the future.

Co-authorship network of co-authors of Todd Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Todd Fox. A scholar is included among the top collaborators of Todd Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd Fox. Todd Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luttringer, Olivier, Todd Fox, Luminita Pricop, et al.. (2021). Secukinumab's effect on structural damage progression in psoriatic arthritis: longitudinal mixture modelling of FUTURE-1 and FUTURE-5. Clinical and Experimental Rheumatology. 39(5). 931–937. 1 indexed citations

Schett, Georg, Xenofon Baraliakos, Filip Van den Bosch, et al.. (2021). Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies. The Journal of Rheumatology. 48(8). 1251–1258. 11 indexed citations

Arbués, Ainhoa, Dominique Brees, Salah‐Dine Chibout, et al.. (2020). TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like Mycobacterium tuberculosis. PLoS Pathogens. 16(2). e1008312–e1008312. 34 indexed citations

Schreiber, Stefan, Jean‐Frédéric Colombel, Brian G. Feagan, et al.. (2019). Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Annals of the Rheumatic Diseases. 78(4). 473–479. 139 indexed citations

McInnes, Iain B., Philip J. Mease, Kristian Reich, et al.. (2019). 257 Secukinumab demonstrates a consistent safety profile with up to 5 years’ treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses. Lara D. Veeken. 58(Supplement_3). 1 indexed citations

Schett, Georg, Xenofon Baraliakos, Filip Van den Bosch, et al.. (2019). FRI0380 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 78. 873–874. 4 indexed citations

McInnes, Iain B., Philip J. Mease, Georg Schett, et al.. (2018). Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Research & Therapy. 20(1). 113–113. 22 indexed citations

Tahir, Hasan, Walter P. Maksymowych, Ernest Choy, et al.. (2018). 173 Comparative effectiveness of secukinumab and golimumab in ankylosing spondylitis assessed by matching-adjusted indirect comparison using pivotal phase III clinical trial data. Lara D. Veeken. 57(suppl_3). 1 indexed citations

McInnes, Iain B., Philip J. Mease, Kristian Reich, et al.. (2018). 185 Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses. Lara D. Veeken. 57(suppl_3). 2 indexed citations

10.

Mease, Philip J., Iain B. McInnes, Kristian Reich, et al.. (2017). Secukinumab Demonstrates Consistent Safety over Long-Term Exposure in Patients with Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses. Queensland's institutional digital repository (The University of Queensland). 69. 2149–2149. 1 indexed citations

11.

Strober, Bruce, Alice B. Gottlieb, Bintu Sherif, et al.. (2017). Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. Journal of the American Academy of Dermatology. 76(4). 655–661. 19 indexed citations

12.

Sofen, Howard, et al.. (2017). Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. Advances in Therapy. 34(6). 1327–1339. 24 indexed citations

13.

Elewski, Boni E., L. Puig, Margaret Mordin, et al.. (2017). Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab. Journal of Dermatological Treatment. 28(6). 492–499. 49 indexed citations

14.

Langley, Richard G., et al.. (2017). Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results.. PubMed. 16(8). 734–741. 15 indexed citations

15.

Kammüller, Michael, Tsen‐Fang Tsai, C.E.M. Griffiths, et al.. (2017). Inhibition of IL‐17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clinical & Translational Immunology. 6(8). e152–e152. 57 indexed citations

16.

Kolbinger, Frank, Andrew Blauvelt, April W. Armstrong, et al.. (2016). Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays. Journal of Dermatological Science. 84(1). e122–e123. 1 indexed citations

17.

Kerkhof, P.C.M. van de, C.E.M. Griffiths, Kristian Reich, et al.. (2016). Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology. 75(1). 83–98.e4. 243 indexed citations

18.

Gottlieb, Alice B., Andrew Blauvelt, Jörg C. Prinz, et al.. (2016). Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.. PubMed. 15(10). 1226–1234. 30 indexed citations

19.

Onicescu, Georgiana, et al.. (2010). Factors associated with cancer survivors’ selection between two group physical activity programs. Journal of Cancer Survivorship. 4(4). 388–398. 11 indexed citations

20.

Hossain, Mohammad, et al.. (2010). Prevalence of silent gastrointestinal complications in maintenance renal transplant population.. PubMed. 21(4). 628–35. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact